Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

5.62
Delayed Data
As of Sep 23
 -0.20 / -3.44%
Today’s Change
3.60
Today|||52-Week Range
12.60
-6.33%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$21.2M

Company Description

Cyclacel Pharmaceuticals, Inc. is a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. It is engaged in discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders, with development operations in two geographic areas, namely the United States and the United Kingdom. The company was founded by Ronald J. Berenson, David Philip Lane and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Contact Information

Cyclacel Pharmaceuticals, Inc.
200 Connell Drive
Berkeley Heights New Jersey 07922
P:(908) 517-7330
Investor Relations:

Employees

Shareholders

Other institutional28.18%
Mutual fund holders2.92%
Individual stakeholders0.14%

Top Executives

Spiro RombotisPresident, Chief Executive Officer & Director
Paul McBarronCOO, CFO, Secretary, Director & Executive VP
David GloverChief Scientist
Susan DavisDirector-Business Development
Bill HarrisCorporate Controller